IRIS
CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.168
EU - Europa 5.813
AS - Asia 2.363
SA - Sud America 449
AF - Africa 152
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 1
Totale 17.958
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.149
UA - Ucraina 1.361
RU - Federazione Russa 720
IE - Irlanda 694
SG - Singapore 669
TR - Turchia 608
SE - Svezia 601
IT - Italia 599
DE - Germania 588
DK - Danimarca 542
HK - Hong Kong 453
BR - Brasile 416
FI - Finlandia 329
KR - Corea 280
CN - Cina 270
FR - Francia 172
GB - Regno Unito 137
CI - Costa d'Avorio 99
MA - Marocco 38
BE - Belgio 29
IN - India 21
BD - Bangladesh 12
EU - Europa 12
NL - Olanda 12
AR - Argentina 10
CA - Canada 10
RO - Romania 9
VE - Venezuela 9
IQ - Iraq 8
MX - Messico 6
PK - Pakistan 6
CO - Colombia 5
PL - Polonia 5
UZ - Uzbekistan 5
VN - Vietnam 5
DZ - Algeria 4
EC - Ecuador 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
IL - Israele 3
JP - Giappone 3
PE - Perù 3
PH - Filippine 3
TN - Tunisia 3
ZA - Sudafrica 3
BG - Bulgaria 2
CH - Svizzera 2
ES - Italia 2
IR - Iran 2
KE - Kenya 2
KG - Kirghizistan 2
NG - Nigeria 2
RS - Serbia 2
AM - Armenia 1
AT - Austria 1
AZ - Azerbaigian 1
CL - Cile 1
CR - Costa Rica 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
ID - Indonesia 1
JM - Giamaica 1
JO - Giordania 1
LB - Libano 1
MD - Moldavia 1
MN - Mongolia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
SV - El Salvador 1
TW - Taiwan 1
UY - Uruguay 1
Totale 17.958
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.397
Fairfield 1.029
Chandler 756
Dublin 694
Boardman 670
Wilmington 548
Ashburn 533
Hong Kong 449
Woodbridge 428
Houston 384
Seattle 367
San Mateo 282
Lawrence 280
Princeton 280
Cambridge 274
New York 264
Singapore 245
Ann Arbor 222
Centro 212
Moscow 190
The Dalles 188
Des Moines 159
San Diego 124
Abidjan 98
Beijing 59
Turin 46
Helsinki 44
London 29
Milan 27
São Paulo 27
Brussels 24
Los Angeles 23
Marche 22
Norwalk 22
Kilburn 20
Guangzhou 19
Shanghai 16
Izmir 15
Washington 15
Pune 14
Rome 14
Belo Horizonte 13
Campinas 13
Dallas 13
Brasília 11
Hounslow 11
Ancona 10
Wuxi 10
Jiaxing 9
Porto Alegre 9
Rio de Janeiro 9
Curitiba 8
Munich 8
Wuhan 8
Acton 7
Prescot 7
San Francisco 7
Santa Clara 7
Turku 7
Yiwu 7
Auburn Hills 6
Chicago 6
Fayetteville 6
Guarulhos 6
Hangzhou 6
Hanover 6
Amsterdam 5
Istanbul 5
New Bedfont 5
Nuremberg 5
Porto 5
Baghdad 4
Dhaka 4
Hanoi 4
Jinhua 4
Piracicaba 4
Três Lagoas 4
Venice 4
Waanrode 4
Warsaw 4
West Jordan 4
Berlin 3
Betim 3
Bogotá 3
Caruaru 3
Casablanca 3
Chiswick 3
Clifton 3
Contagem 3
Dalian 3
Florence 3
Florianópolis 3
Fortaleza 3
Frankfurt am Main 3
Montréal 3
Mountain View 3
Nantong 3
Natal 3
San Giuliano Terme 3
San Jose 3
Totale 10.841
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 216
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 184
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 126
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 124
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 117
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 117
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 113
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 112
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 110
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. 109
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy 108
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 108
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 107
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 107
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. 106
Progress of molecular targeted therapies for advanced renal cell carcinoma. 106
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 105
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 103
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 103
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 102
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 102
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 102
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 98
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 98
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. 98
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 97
Cancer of pancreas. 95
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 95
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 95
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 95
New target therapies in advanced pancreatic cancer. 94
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 94
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 92
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 92
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. 91
A cost-benefit analysis of chemotherapy for gastric cancer. 90
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 90
Transient sunitinib resistance in gastrointestinal stromal tumors. 90
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 89
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 89
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 89
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. 88
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 88
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 88
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 88
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 87
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 87
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 87
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. 85
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 85
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 84
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 84
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 83
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. 82
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 82
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 82
c-erbB-2 and common prognostic factors in breast cancer patients. 81
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. 80
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. 80
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 80
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 80
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 79
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 78
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 78
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. 77
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. 77
Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. 77
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 77
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 77
Panitumumab for the treatment of metastatic colorectal cancer: A review 77
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 77
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. 76
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. 76
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 76
Metabolic alterations in renal cell carcinoma 75
Trattamento del carcinoma del pancreas. Attualità e prospettive 75
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 74
5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. 74
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. 73
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 73
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 73
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 73
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. 72
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 72
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. 72
A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. 72
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Protein in Urothelial Cell Carcinoma of Human Bladder 72
Role of STAT3 pathway in genitourinary tumors 72
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 72
Insulin-like Growth Factor (IGF) 1 and 2 help to predict disease outcome in GIST patients 71
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. 71
Locoregional treatments of unresectable liver metastases from colorectal cancer. 71
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 71
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 70
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. 70
Pain and its treatment in hospitalized patients with metastatic cancer. 70
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 70
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 70
Gastric cancer: Therapeutic choices in advanced disease 70
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. 70
Totale 8.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.353
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.353
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020428 0 0 0 0 0 0 0 0 0 0 32 396
2020/20214.054 203 479 579 92 500 283 404 265 360 318 375 196
2021/20221.938 113 525 16 69 19 147 72 128 131 208 129 381
2022/20232.719 310 301 215 168 191 323 3 123 839 13 182 51
2023/20241.739 328 31 73 352 321 326 35 34 0 27 15 197
2024/20253.287 387 341 189 27 131 55 337 140 1.103 421 156 0
Totale 18.120